Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2021 Biotech Stock Picking Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: technetium who wrote (194)	8/14/2021 4:27:56 PM
From: ErikOtto	1 Recommendation Recommended By BulbaMan Respond to of 307

It's really been a brutal year, especially in small and mid cap biotech, and the indices aren't reflective of it at all. It seems like FDA is showing a great deal more scrutiny, and there are many pricing paradigms being floated in government that could negatively impact the sector. Add to that a slew of bad data releases and trial holds and here we are. I am really hoping things improve in the second half. Honestly it wouldn't be that bad if I thought these pricing plans proposed in government made any sense. The problem is with the insurance system, PBMs and rebates - until they address that fundamental issue nothing matters - it will only stifle innovation but not really reduce prices for patients. Then you have situations like the BIIB approval and ridiculous list price overreach that is just sickening and only brings more concern about the sector. It feels like the system is breaking down and regulators / government are grasping at straws trying to fix it. Anyway, I am saying all this not just to be a negative nellie, but to say thanks to technetium for continuing to tabulate the stats here, especially with the terrible sector sentiment. I for one appreciate it and welcome any associated commentary.

To: technetium who wrote (194)

8/21/2021 11:42:25 PM

From: technetium

Read Replies (1) | Respond to of 307

Though it was a good week for GOVX and a few others, it was pretty bad generally, both for the indices and for the contest participants. At this point all but the top 5 are underwater, and even those with current positive returns have shown substantial erosion from where they were a month or so ago.

ERIK is in the lead.

The rest of the best, those in positions 6-10 YTD, are close to breaking even or within 4% of their original investment. Does that correspond to a 95% confidence range, as in a statistically insignificant difference from zero loss? No, I don’t buy that argument, I’m just having fun with words, not numbers. ;-)

As mentioned, although SNOA looked promising Thursday, it didn’t make the list for the top five gainers for the week.

		Report Time Ranges
			From	To
		Recent	8/14/21	8/21/21
		YTD	12/31/2020	8/21/21
Index Performance
			Symbol	Recent	YTD
			^IXIC	-0.73%	14.17%
			^NBI	-1.75%	8.73%
			^SPSIBI	-1.95%	-13.18%
Share Performance
Recent				YTD
Top 5		Bottom 5		Top 5		Bottom 5
GOVX	41.687%	SESN	-52.607%	ANVS	392.04%	OTIC	-80.68%
CBLI	20.539%	FATE	-22.719%	PDSB	377.57%	FREQ	-79.50%
CDTX	16.667%	ASLN	-18.021%	PAND	304.04%	CNCE	-74.76%
VRDN	15.329%	CMMB	-17.992%	AVXL	240.00%	ATHA	-71.91%
AFIB	14.619%	PCVX	-17.672%	NURO	220.57%	TARA	-71.83%
Top 10 Portfolio Performance YTD
			ERIK	64.32%
			DNAJOE	59.78%
			WINTER	51.25%
			BMAZ	37.75%
			DANIEL	35.65%
			BIOSCI	-0.24%
			TWONE	-2.40%
			ECCU	-3.11%
			ALONER	-3.64%
			HAMMER	-3.65%
Average and Median Portfolio Performance
	Avg Recent	Avg YTD	Median Recent		Median YTD
	-$2984.81	-12.70%	QUID	-$2428.56	SQUARE	-21.36%
	-3.176%	-12.70%	TOMATO	-2.971%	SQUARE	-21.36%